Research programme: influenza vaccines - Nykode Therapeutics
Latest Information Update: 03 Dec 2021
At a glance
- Originator Vaccibody
- Developer Nykode Therapeutics
- Class Influenza virus vaccines; Protein vaccines
- Mechanism of Action Antigen presenting cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 23 Nov 2021 Vaccibody is now called Nykode Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Influenza-virus-infections(Prevention) in Norway (Parenteral)
- 01 Nov 2012 Early research in Influenza virus infections in Norway (Parenteral)